Tag: Policy

Montana’s first experimental treatment review board has brought three longevity heavyweights into the state’s effort to expand access to experimental therapies. How much regulation is too much? Many people in the longevity field will tell you that regulation is holding it back. Sensible oversight of novel therapies is essential, but an overly cautious interpretation of...

In this follow-up interview, we speak with Gabriel Cian about how the 2060 ecosystem has evolved since last year’s Forum, what he learned from the first edition, and how he is thinking about investment, scientific credibility, health optimization, policy, and the future of longevity in Europe. Last year, we spoke about your path from software...

In a recently published perspective paper, the author argues that the UK's official health guidelines on physical activity and protein intake should be revised to recommend levels necessary to achieve optimal health, rather than the bare minimum currently recommended [1]. From bare minimum to optimizing for healthspan Current government guidelines on nutrition and physical activity...

The longevity field remains small and starved for resources, especially the subfield devoted to the fundamental biology of aging, despite near-universal agreement that solving aging requires understanding it first. With VCs looking for clinical successes and state funding drying up for many projects, some enthusiasts are turning to a nonprofit model. That path is anything...

We have spoken with Reason from Repair Biotechnologies about his company's lead candidate, REP-0004, a drug targeting the liver to reduce excess intracellular free cholesterol. The FDA has granted Repair Bio an orphan drug indication, and the company is aiming for clinical trials by mid-2027. Our conversation also touches on the regulatory challenges and the...

The FDA views aging as an inevitability, not a medical target. However, with Life Biosciences moving the first cellular reprogramming therapy into human trials this year, things might be changing there. If this technique works in resetting the biological age of the human eye, the entire multibillion-dollar longevity industry could move to the center of...